


What science can do

AstraZeneca Annual Report and Form 20-F Information 2015



AstraZeneca at a glance


AstraZeneca is a global, science-led biopharmaceutical business...
 ...with an on-market portfolio in our chosen therapy areas.

Respiratory, Inflammation and Autoimmunity 	Cardiovascular and Metabolic diseases 	Oncology 	Infection, Neuroscience and Gastrointestinal 
\$4,987m Product Sales 2014: \$5,063m 2013: \$4,677m	\$9,489m Product Sales 2014: \$9,802m 2013: \$8,830m	\$2,825m Product Sales 2014: \$3,027m 2013: \$3,193m	\$6,340m Product Sales 2014: \$8,203m 2013: \$9,011m

Highlights			
<ul style="list-style-type: none"> > Respiratory sales up by 7%, including 25% in Emerging Markets, before completion of the acquisition of Takeda's respiratory business > Sales of <i>Symbicort</i> down by 3% 	<ul style="list-style-type: none"> > <i>Brilinta/Brilique</i> sales up by 44%, including 64% in the US > Diabetes sales up by 26%, including 76% in Emerging Markets > Sales of <i>Crestor</i> fell by 3% reflecting competition from generic statins and pricing pressure 	<ul style="list-style-type: none"> > Oncology sales up by 7% > New Oncology included for the first time (comprising <i>Lynparza</i>, <i>Iressa</i> (US) and <i>Tagrisso</i>) > <i>Lynparza</i> launched in 15 markets and sales of \$94 million 	<ul style="list-style-type: none"> > Sales of <i>Nexium</i> declined by 26%, including 52% in the US following loss of exclusivity > Sales of <i>Seroquel XR</i> fell by 12% and <i>Synagis</i> fell by 26%

 Sales and Marketing from page 48, Financial Review from page 62 and Geographical Review from page 227


We have distinctive R&D capabilities, a growing late-stage pipeline...



NMEs in Phase III, pivotal Phase II or under regulatory review

15

2015	15
2014	13
2013	11
2012	6







 Therapy Area Review from page 24 and Research and Development from page 42

...and a strong global commercial presence, with strength in Emerging Markets.

North America	Europe	International and Japan
<p>\$10,007m</p> <p>Product Sales 2014: \$10,710m 2013: \$10,328m</p>	<p>\$5,323m</p> <p>Product Sales 2014: \$6,638m 2013: \$6,658m</p>	<p>\$8,311m</p> <p>Product Sales 2014: \$8,747m 2013: \$8,725m</p>
Employees		
7,600	5,900	21,900
Highlights		
<ul style="list-style-type: none"> > Sales in the US declined by 6% reflecting entry of generic <i>Nexium</i> products and adverse <i>Synagis</i> guideline changes > Favourable performances were delivered by <i>Brilinta</i>, <i>Farxiga</i>, <i>Bydureon</i> and <i>Lynparza</i> as well as the acquired Respiratory medicines, <i>Tudorza</i> and <i>Daliresp</i> > Sales in Canada grew by 4% 	<ul style="list-style-type: none"> > Sales declined by 6% > Strong growth for Diabetes medicines was offset by generic competition facing <i>Crestor</i> and <i>Seroquel XR</i> > 14% decline in <i>Symbicort</i> sales reflected adverse pricing movements driven by competition from analogues in key markets 	<ul style="list-style-type: none"> > Emerging Markets revenue grew by 12% to \$5,822 million, including China sales growth of 15% > Sales in Japan grew by 4% to \$2,020 million > Opened facility in Russia

Business Review from page 42

Our talented employees are committed to achieving our Purpose in a sustainable way...

<p>61,500 employees worldwide</p> 	<p>8,900 employees in R&D</p> 	<p>12,500 employees in Manufacturing and Supply</p> 
<p>Increasing our proximity to bioscience clusters and co-locating around three strategic R&D centres</p>		
<p>> Cambridge, UK</p> 	<p>> Gaithersburg, Maryland US</p> 	<p>> Gothenburg, Sweden</p> 

Employees from page 52

...and our disciplined capital allocation enables commitment to a progressive dividend.

\$3,443m

Net cash shareholder distributions
increased to \$3,443 million

2015	\$3,443m
2014	\$3,242m
2013	\$2,979m

\$2.80

Dividend per Ordinary Share
unchanged

2015	\$2.80
2014	\$2.80
2013	\$2.80

All growth rates at CER.
All employee numbers are approximate as at 31 December 2015.